DXC, which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #4 (Sell) further confirms weakness in DXC.
A key reason for this move has been the negative trend in earnings estimate revisions. For the full year, we have seen 10 estimates moving down in the past 30 days, compared with no upward revisions. This trend has caused the consensus estimate to trend lower, going from $9.04 a share a month ago to its current level of $8.18.
The stock also has seen some pretty dismal trading lately, as the share price has dropped 18.1% in the past month.